drugset / Trial / NCT03461445

Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients

NCT03461445 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

Previous studies have shown that elderly patients experience higher trough levels of tacrolimus and are more sensitive to the effects of medications, they experience higher occurrence and severity of such medication related toxicities. Therefore, the investigators hypothesize that by transitioning patients from tacrolimus immediate release to Envarsus ®, the peak-dose effect will be eliminated or attenuated, leading to a significant decrease in neurocognitive toxicities in the older patient population.

Timeline

Start
2018-04-01
Primary completion
2023-07-31
Completion
2023-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule — —

Indications